Interview with: Paul M. Walker, M.D., Ph.D., F.R.C.S.C, Director, President and CEO - featuring: their diagnostics products that enable clinicians to institute appropriate treatment in a manner of minutes; their Sepsis assay the EAA™ is the first FDA approved assay for the early diagnosis of sepsis, one of the major health care challenges worldwide.

Spectral Diagnostics Inc. (SDI-TSX)

wpe3.jpg (15694 bytes)

CURRENT ISSUE    |   COVER ARCHIVES    |       INDEX      |    CONTACT    |    FINANCIALS    |     MARKETING SERVICES   |    HOME PAGE


CEOCFO
-Members Login

Become A Member!

This is a printer friendly page!

Spectral Diagnostics is establishing a distribution network in Europe with companies who have focused in the area of sepsis and blood purification and are capable of properly representing their diagnostic products to clinicians

wpe11.jpg (3611 bytes)

Healthcare
Disease Management
(SDI-TSX)


Spectral Diagnostics Inc.


wpe1A.jpg (11530 bytes)

Paul M. Walker, M.D., Ph.D., F.R.C.S.C
Director, President and CEO

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
Published - April 12, 2007



wpe20.jpg (13926 bytes)


disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.


“With respect to our Endotoxin Activity Assay the EAA™, we have a joint arrangement with Toray Medical Products a division of Toray Industries, Inc. in Japan. We are establishing a distribution network within Europe. We have concluded agreements in Italy and Spain and we are looking to conclude distribution agreements for the rest of Europe in the very near future. These distribution companies have been carefully chosen and are focused in the area of sepsis, blood purification etc., and are capable of distributing our product properly and representing it properly to the clinicians who will be in the position of ordering this. A lot of our marketing takes place with the presentation of our clinical data, which we have gathered over the past couple of years from clinical trials. We have been doing this around the world at a number of different centers. We have 7 or 8 in the United States, several more in Europe etc.; we are quite global in our opinion leader support.” - Paul M. Walker, M.D., Ph.D., F.R.C.S.C

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

.